NURO NeuroMetrix Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NURO

Price (delayed)

$3.51

Market cap

$7.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.26

Enterprise value

$6.01M

NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. The Company has ...

Highlights
NeuroMetrix's debt has decreased by 36% YoY and by 13% QoQ
NURO's net income has shrunk by 59% YoY and by 22% QoQ
NeuroMetrix's gross profit has decreased by 37% YoY and by 17% from the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.neurometrix.com
Peers: IART SYK MDT

Key stats

What are the main financial stats of NURO
Market
Shares outstanding
2.01M
Market cap
$7.06M
Enterprise value
$6.01M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.37
Price to sales (P/S)
1.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.14
Earnings
Revenue
$5.27M
EBIT
-$7.98M
EBITDA
-$7.91M
Free cash flow
-$7.23M
Per share
EPS
-$6.26
Free cash flow per share
-$3.99
Book value per share
$9.44
Revenue per share
$2.91
TBVPS
$11.4
Balance sheet
Total assets
$20.66M
Total liabilities
$1.91M
Debt
$209,337
Equity
$18.76M
Working capital
$18.3M
Liquidity
Debt to equity
0.01
Current ratio
10.91
Quick ratio
9.78
Net debt/EBITDA
0.13
Margins
EBITDA margin
-150.2%
Gross margin
62%
Net margin
-151.5%
Operating margin
-165%
Efficiency
Return on assets
-37.1%
Return on equity
-39.8%
Return on invested capital
-42.4%
Return on capital employed
-42.4%
Return on sales
-151.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NURO stock price

How has the NeuroMetrix stock price performed over time
Intraday
-1.68%
1 week
-5.14%
1 month
-3.84%
1 year
-55.15%
YTD
-2.5%
QTD
-5.14%

Financial performance

How have NeuroMetrix's revenue and profit performed over time
Revenue
$5.27M
Gross profit
$3.27M
Operating income
-$8.7M
Net income
-$7.98M
Gross margin
62%
Net margin
-151.5%
NeuroMetrix's net margin has shrunk by 131% YoY and by 37% QoQ
NURO's operating margin has shrunk by 131% YoY and by 36% QoQ
NURO's net income has shrunk by 59% YoY and by 22% QoQ
NURO's operating income has dropped by 58% year-on-year and by 22% since the previous quarter

Growth

What is NeuroMetrix's growth rate over time

Valuation

What is NeuroMetrix stock price valuation
P/E
N/A
P/B
0.37
P/S
1.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.14
NURO's EPS is down by 12% YoY
The P/B is 65% below the 5-year quarterly average of 1.1 but 30% above the last 4 quarters average of 0.3
The equity has declined by 15% year-on-year and by 7% since the previous quarter
NURO's revenue is down by 31% year-on-year and by 11% since the previous quarter
The stock's price to sales (P/S) is 29% less than its 5-year quarterly average of 1.8 but 27% more than its last 4 quarters average of 1.0

Efficiency

How efficient is NeuroMetrix business performance
NURO's ROS has shrunk by 131% YoY and by 37% QoQ
NURO's ROA has plunged by 80% YoY and by 27% from the previous quarter
NeuroMetrix's ROE has plunged by 79% YoY and by 27% from the previous quarter
The ROIC has plunged by 66% YoY and by 26% from the previous quarter

Dividends

What is NURO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NURO.

Financial health

How did NeuroMetrix financials performed over time
NURO's total liabilities is up by 43% QoQ and by 19% YoY
The current ratio has contracted by 35% from the previous quarter and by 33% YoY
NeuroMetrix's debt is 99% lower than its equity
NeuroMetrix's debt has decreased by 36% YoY and by 13% QoQ
The equity has declined by 15% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.